Complete response in a patient with a metastatic cutaneous melanoma
Keywords:
Melanoma. Quimioterapia. Inmunoquimioterapia.Abstract
Background. The management of patients with disseminated disease is a difficult problem. There is currently no consensus on the standard first-line treatment for metastatic melanoma. We present a case because of his exceptional evolution. Results. A 43 year old male diagnosed in 1999 with malignant melanoma stage IIA. In May 2000 hepatic and splenic metastases were detected. He received 6 cycles of biochemotherapy (cisplatin and DTIC, plus interleukin-2 and interferon-α) and another 6 cycles with single immunotherapy (interleukin-2 and interferon-α). Today, the patient is still alive and without evidence of disease. Conclusion. Metastatic cutaneous melanoma, sometimes presents an unusual, favourable evolution. In the near future, the methods of detection of molecular markers are expected to identify factors involved in this type of response. Furthermore, new targeted therapies may become essential to maintain this positive trend.Downloads
References
1. GERSHENWALD JE, MORTON DL, THOMPSON JF, KIRKWOOD JM, SOONG S, BALCHET CM et al. Collaborators of the AJCC/UICC Melanoma Task Force. Staging and prognostic factors for stage IV melanoma: initial results of an American Joint Committee on Cancer (AJCC) international evidence-based assessment of 4.895 melanoma patients. J Clin Oncol 2008; 26 (Supl): abstract 9035.
https://doi.org/10.1200/jco.2008.26.15_suppl.9035
2. EGGERMONT AM, KIRKWOOD JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40: 1825-1836.
https://doi.org/10.1016/j.ejca.2004.04.030
3. ETON O, LEGHA SS, BEDIKIAN AY, LEE JJ, BUZAID AC, HODGES C et al. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial. J Clin Oncol 2002; 20: 2045-2052.
https://doi.org/10.1200/JCO.2002.07.044
4. IVES NJ, STOWE RL, LORIGAN P, WHEATLEY K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2.621 patients. J Clin Oncol 2007; 25: 5426-5434.
https://doi.org/10.1200/JCO.2007.12.0253
5. BRAND CU, ELLWANGER U, STROEBEL W, MEIER F, SCHLAGENHAUFF B, RASSNER G et al. Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997; 79: 2345-1353.
https://doi.org/10.1002/(SICI)1097-0142(19970615)79:12<2345::AID-CNCR8>3.0.CO;2-K
6. Melanoma of the skin. En: Edge SB, Byrd DR, Compton CC et al, editores. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer, 2010: 325-344.
https://doi.org/10.1007/978-0-387-88441-7_31
7. POTTI A, MOAZZAM N, LANGNESS E, SHOLES K, TENDULKAR K, KOCH M et al. Immunohistochemical determinación of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol 2004; 130: 80-86.
https://doi.org/10.1007/s00432-003-0509-8
8. MEIRIÑO R, MARTÍNEZ E, MARCOS M, VILLAFRANCA E, DOMÍNGUEZ MA, ILLARRAMENDI JJ et al. Factores pronósticos en el melanoma maligno cutáneo. An Sist Sanit Navar 2001; 24 (Supl. 1): 167-172.
9. MINOR DR, MOORE D, KIM C, KASHANI-SABET M, VENNA SS, WANG W et al. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy. Oncologist 2009; 14: 995-1002.
https://doi.org/10.1634/theoncologist.2009-0083
10. VEGA EF, MAYORDOMO JI, MEANA JA, VALLADARES M, FLORIÁN J, BRETÓN JJ et al. Bioquimioterapia ambulatoria con cisplatino, dacarbacina, inteleucina-2 e interferón alfa en pacientes con melanoma avanzado. Estudio multicéntrico en 44 pacientes. Rev Oncol 2003; 5: 79-87.
https://doi.org/10.1007/BF02728200
11. HODI FS, O'DAY SJ, MCDERMOTT DF, WEBER RW, SOSMAN JA, HAANEN JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
https://doi.org/10.1056/NEJMoa1003466
12. FLAHERTY KT, PUZANOV I, KIM KB, RIBAS A, MCARTHUR GA, SOSMAN JA et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
https://doi.org/10.1056/NEJMoa1002011
13. KEFFORD R, ARKENAU H, BROWN PM. Phase I/II study of GSK218436, a selective inhibitor of oncogenic mutante BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010; 28 (Supl): 611s (abstract 8503).
https://doi.org/10.1200/jco.2010.28.15_suppl.8503
14. HANDOLIAS D, HAMILTON AL, SALEMI R, TAN A, MOODIE K, KERR L et al. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT. Br J Cancer 2010; 102: 1219-1223.
https://doi.org/10.1038/sj.bjc.6605635
15. KIRKWOOD JM, GONZALEZ R, REINTGEN DS, CLINGAN PR, MCWILLIAMS RR, ILARIA RL et al. A phase II study of tasisulam sodium (LY573636) as second-line treatment for patients with unresectable or metastatic melanoma. J Clin Oncol 2010; 28 (Supl 15): abstract 8541.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2011 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
